Elanco Animal Health (NYSE:ELAN) Sets New 12-Month High After Analyst Upgrade

Key Points

• Elanco Animal Health's shares hit a new 52-week high after an upgrade from JPMorgan Chase, shifting the rating from neutral to overweight with a new price target of $24.00.
• Analysts are generally positive about Elanco, with two rating it as a Strong Buy and a consensus rating of Moderate Buy, indicating growing confidence in the company's performance.
• Elanco reported a quarterly EPS of $0.26, exceeding expectations, with a revenue of $1.24 billion, which was also above consensus estimates.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) shares reached a new 52-week high on Wednesday after JPMorgan Chase & Co. upgraded the stock from a neutral rating to an overweight rating. JPMorgan Chase & Co. now has a $24.00 price target on the stock, up from their previous price target of $18.00. Elanco Animal Health traded as high as $21.76 and last traded at $20.49, with a volume of 6639326 shares trading hands. The stock had previously closed at $20.66.

Several other analysts have also recently commented on the stock. Piper Sandler boosted their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Leerink Partners upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target on the stock in a research note on Thursday, July 17th. Zacks Research upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 3rd. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. Finally, William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Elanco Animal Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.14.

Institutional Trading of Elanco Animal Health

Several hedge funds have recently made changes to their positions in the business. Allworth Financial LP grew its holdings in Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the last quarter. NBC Securities Inc. bought a new position in Elanco Animal Health during the 1st quarter valued at about $40,000. First Horizon Advisors Inc. grew its holdings in Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock valued at $53,000 after purchasing an additional 2,414 shares during the last quarter. Wealthquest Corp bought a new position in Elanco Animal Health during the 1st quarter valued at about $56,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock valued at $58,000 after purchasing an additional 2,922 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

The company has a market capitalization of $10.18 billion, a P/E ratio of 23.82, a P/E/G ratio of 3.81 and a beta of 1.65. The firm's fifty day moving average is $17.98 and its 200 day moving average is $14.23. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm's revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.